Most women with invasive BC (n = 28/31, 90%) received chemotherapy ± anti‐HER2 antibody therapy with neoadjuvant (n = 13, 46%) or adjuvant regimes (n = 15, 54%). This evidence concerns the gene ERBB2 and breast cancer.